Gail P Risbridger

21PUBLICATIONS
209CO-AUTHORS
Molecular targetsPredictive and prognostic markersGene expression (incl. microarray and other genome-wide approaches)Cancer therapy (excl. chemotherapy and radiation therapy)Gene mapping
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Apr 25, 2025
p-AKT Protein Expression Predicts Response to AKT Inhibitor Combined with Docetaxel Therapy in Adenocarcinoma and Neuroendocrine Prostate Cancer.

Hipacia Werneck Gomes, Natalie L Lister, Shivakumar Keerthikumar

|Oct 25, 2024
Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.

Razia Rahman, Muhammed H Rahaman, Adrienne R Hanson

|Aug 08, 2024
CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.

Razia Rahman, Muhammed H Rahaman, Adrienne R Hanson

|Jun 08, 2024
FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer.

Zifeng Wang, Scott L Townley, Songqi Zhang

|Mar 07, 2024
Defining the challenges and opportunities for using patient-derived models in prostate cancer research.

W Nathaniel Brennen, Clémentine Le Magnen, Sofia Karkampouna

Pageof 4